Neuromyelitis optica (NMOSD) trials in Argentina
1 of 3 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleRegistry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
- Where
- Buenos Aires
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT05966467